A carregar...
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China
BACKGROUND: Hepatitis C is the second fastest growing infectious disease in China. The standard-of-care for chronic hepatitis C in China is Pegylated interferon plus ribavirin (PR), which is associated with tolerability and efficacy issues. An interferon- and ribavirin-free, all-oral regimen compris...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5892899/ https://ncbi.nlm.nih.gov/pubmed/29634736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0195117 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|